GlassScriptPhysician profile
Susan M Jensen
NPI 1134185556
$8,489.43
in general payments reported to CMS, 2019-2025
33 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $938 · 2021: $1,478 · 2022: $1,566 · 2023: $1,556 · 2024: $1,356 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,038.40 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,004.59 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $910.73 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $718.33 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $613.13 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.29 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Amgen INC. | $414.74 | 2019-2025 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $389.41 | 2019-2024 | Xarelto, Spravato |
| Pfizer INC. | $379.95 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $337.45 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $266.87 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $210.73 | 2019-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.87 | 2022-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $167.52 | 2020-2024 | |
| Neuronetics, INC. | $148.32 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $147.65 | 2020-2021 | |
| Inspire Medical Systems, INC. | $146.50 | 2025 | Inspire |
| Exact Sciences Corporation | $136.88 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $135.75 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $103.27 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $97.12 | 2021-2023 | |
| Alkermes, INC. | $56.53 | 2022 | |
| Biogen, INC. | $54.92 | 2021 | |
| Astellas Pharma US INC | $40.37 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $36.81 | 2021 | |
| Abbott Laboratories | $36.54 | 2024 | Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $36.41 | 2020 | |
| Idorsia Pharmaceuticals US INC | $31.08 | 2022-2023 | Quviviq |
| Recordati_rare_diseases_inc. | $24.28 | 2024 | Isturisa, Signifor Lar |
| Ironwood Pharmaceuticals, INC | $19.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.59 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.63 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.